Arthritis drug safety checked in kids over two years
NCT ID NCT01673919
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 23 times
Summary
This study looked at the long-term safety of the drug tocilizumab (RoActemra/Actemra) in children with a type of arthritis called polyarticular-course juvenile idiopathic arthritis. Seven children who had already finished a main study received the drug every 4 weeks for up to 2 years. The main goal was to track any side effects, including serious ones or infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Le Kremlin-Bicêtre, 94275, France
-
Study site
Montpellier, 34295, France
-
Study site
Paris, 75679, France
-
Study site
Paris, 75743, France
Conditions
Explore the condition pages connected to this study.